Surface Modification Strategies for Biofunctionalization of Nanoparticles

Prakash D. Nallathamby, Ph.D Assistant Research Professor Department of Aerospace and Mechanical Engineering Bioengineering Program <u>https://sites.nd.edu/pdnano</u>











Major Areas of Focus





ERSITYOF REDAME ww.nd.edu/~amebio

Surface Modifications Are Necessary to Immobilize Nanoparticles on Varied Materials









E. coli

91


88.4

87.4

85

Managed by UT-Battelle for the Department of Energy

Surface Modifications Are Necessary to Attenuate Probe Toxicity



VERSITY OF


http://www.nd.edu/~amebio

Chem. Res. Toxicol., 2013, 26 (6), pp 904-917





Probes with Low toxicity Were Used to Monitor Live Zebrafish Embryos for 72h









Surface Modifications to Bait-and-Switch Microbes

THE JOURNAL OF PHYSICAL CHEMISTRY C

Article pubs.acs.org/JPCC


Single Nanoparticle Plasmonic Spectroscopy for Study of Charge-Dependent Efflux Function of Multidrug ABC Transporters of Single Live *Bacillus subtilis* Cells

Lauren M. Browning, Kerry J. Lee, Prakash D. Nallathamby, Pavan K. Cherukuri, Tao Huang, Seth Warren, and Xiao-Hong Nancy Xu*

Department of Chemistry and Biochemistry, Old Dominion University, Norfolk, Virginia 23529, United States

Supporting Information

ABSTRACT: Multidrug membrane transporters can selectively extrude a wide variety of structurally and functionally unrelated substrates, and they are responsible for ineffective treatment of a wide range of diseases (e.g., infection and cancer). Their underlying molecular mechanisms remain elusive. In this study, we functionalized Ag NPs (11 nm in diameter) with two biocompatible peptides (CALNNK, CALNNE) to prepare positively and negatively charged Ag-peptide NPs (Ag-CALNNK NPs^{+ ξ}, Ag-CALNNE NPs^{-4 ζ}), respectively. We used them as photostable plasmonic imaging probes to study chargedependent efflux kinetics of BmrA (ABC) membrane trans-




porter of single live *Bacillus (B.) subtilis* cells. Two strains of the cells, normal expression of BmrA (WT) or devoid of BmrA (Δ BmrA), were used to study the charge-dependent efflux kinetics of single NPs upon the expression of BmrA. The NPs (1.4 nM) were stable (non-aggregation) in a PBS buffer and biocompatible to the cells. We found the high-dependent accumulation of the intracellular NPs in both WT and Δ BmrA upon the charge and concentration of NPs. Notably, the accumulation rates of the positively charged NPs in single live WT cells are nearly identical to those in Δ BmrA cells, showing independence upon the expression of BmrA. In contrast, the accumulation rates of the negatively charged NPs in Single live WT. The accumulation of positively charged NPs in WT are much lower than in Δ BmrA, showing high dependence upon the expression of BmrA. In contrast, the accumulation of positively charged NPs in both WT and Δ BmrA increases nearly proportionally to the NP concentration. The accumulation of positively charged NPs in Δ BmrA, but not in WT, also increases nearly proportionally to the NP concentration. These results suggest that both negatively and positively charged NPs out of the WT. This study shows that single NP plasmon spectroscopy can serve as a powerful tool to identify single plasmonic NPs and to probe the charge-dependent efflux kinetics and function of single membrane transporters in single live cells in real time.





UNIVERSITY OF NOTRE DAME http://www.nd.edu/~amebio

Non- Modified Nanoparticles are Immediately Ejected by Bacteria










Surface Tuned Nanoparticles Accumulate in Bacteria









Surface Modifications to Mask Systemic Toxicity

POISON CHEMISTRY - WHITE ARSENIC

Arsenic is a notorious poison; colourless, odourless white arsenic was a popular choice for poisoners, and was commonly known as 'The King of Poisons'.

ARSENIC (III) OXIDE

HISTORY

White arsenic has been known for centuries. In Ancient Rome, Nero's supposed use of it to poison his brother & become emperor is one of the first documented cases.

In the 17th & 18th centuries, white arsenic's use as a poison was widespread, and earned it the nickname 'inheritance powder'. However, its usage as a poison rapidly declined after the development of chemical tests.

Around 50.000 tonnes of arsenic trioxide are still produced annually, and used as a precursor to a range of compounds. It's also been used as a treatment for some leukaemias.

EFFECTS



HEADACHE

DIARRHOEA







DISCOLOURATION

OF NAILS



VOMITING &

METALLIC TASTE


CONVULSIONS CONVULSIONS COMA & DEATH

BREATH SMELLS

OF GARLIC


Symptoms usually appear around 30 minutes after ingestion. Arsenic interferes with cell enzymes, respiration and mitosis. The skin, lungs, kidneys and liver are the major organs affected, with death occuring either from circulatory inefficiency, or liver or kidney failure.





Chelating agents, such as the above compounds, bind the arsenic ions and prevent them from inhibiting enzymes. However, chelation therapy itself can have side effects. Dimercaprol has been largely superseded by 2,3-dimercapto-1-propanesulfonic acid.

DETECTION



The Marsh Test involves reaction of a sample with zinc and acid. If arsenic is present, it is converted to arsine gas. Heating arsine decomposes it; a silver-black deposit of arsenic is formed on cooling. Modern spectroscopic methods are now used instead of this test.

© COMPOUND INTEREST 2015 - WWW.COMPOUNDCHEM.COM | Twitter: @compoundchem | Facebook: www.facebook.com/compoundchem This graphic is shared under a Creative Commons Attribution-NonCommercial-NoDerivatives licence.



ITYOF



http://www.nd.edu/~amebio

Drug Delivery

Smart Human-Serum-Albumin–As₂O₃ Nanodrug with Self-Amplified Folate Receptor-Targeting Ability for Chronic Myeloid Leukemia Treatment

Yongbo Peng⁺, Zilong Zhao⁺,* Teng Liu⁺, Xiong Li, Xiaoxiao Hu, Xiaoping Wei, Xiaobing Zhang, and Weihong Tan^{*}

Abstract: Arsenic trioxide (ATO, As_2O_3) is currently used to treat acute promyelocytic leukemia. However, expanding its use to include high-dose treatment of other cancers is severely hampered by serious side effects on healthy organs. To address these limitations we loaded ATO onto folge (EA) labeled (FDA) for the treatment of acute promyelocytic leukemia (APL) with a complete remission rate of 83–95 %.^[1] ATO affects numerous intracellular signal transduction pathways and alters cellular function, resulting in cellular apoptosis, inhibition of angiogenesis and the promotion of differentia.

human serum a (GSH) based on bond, and we ta HSA-ATO. FA-i receptor-β-positi cells, resulting i Furthermore, the in CML cancer even more recru In vitro and in v significantly alle efficacy of ATO



Arsenic trioxide (ATO, As₂O₃) is a front-line antineoplastic agent approved by the U.S. Food and Drug Administration

Dr. T. Liu,^[4] Prof. Dr. X. Li Department of Infectious Diseases, Xiangya Hospital, Central South University Changsha, 410008 (China) of insoluble arsenite compounds with transition metal ions or platinum-based drugs^[5hc] Such strategies open new avenues to improve the therapeutic index of ATO. However, the encapsulated ATO shows attenuated cytotoxicity compared to free ATO, resulting from the incomplete release from the insoluble arsenic compounds^[5b] Therefore, we contemplated the rational design of a delivery platform that would expand the therapeutic applications of arsenic in CML, but without the limitations noted above.

Human serum albumin (HSA) is the most abundant endogenous protein in plasma. It has been found that HSA has extraordinary binding affinity not only for endogenous solutes in plasma, including metal ions, fatty acids, amino acids, and metabolites,^[6] but also for many exogenous drugs, for example, Paclitaxel (PTX), platinum-based drugs, and Chlorin e6.^[7] HSA has a long plasma half-life of 19 days and



^[*] Dr. Y. Peng,^[4] Prof. Dr. Z. Zhao,^[4] Dr. T. Liu,^[4] Dr. X. Hu, Prof. Dr. X. Zhang, Prof. Dr. W. Tan Molecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Life Sciences, and Aptamer Engineering Center of Hunan Province, Hunan University Changsha 410082 (China) E-mail: tan@chem.ufl.edu zlzhao@hnu.edu.cn

Outline of the talk

- Section I
 - Common chemical techniques employed to modify surface of nanoparticles

• Section II

- Characterization of chemical functional groups on nanoparticles
- Section III
 - Common conjugation techniques
- Section IV
 - Published examples of how surfaces are modified to meet end user needs
- Section V
 - Interesting reads







Common Molecules for Surface Modifications

- Thiols (-SH)
 - Applicable to modifying gold, silver, copper and thiol reactive metals like molybdenum
- Silanes (Orthosilicates)
 - Applicable to modifying glass, silica and oxide surfaces that have been treated to overexpress –OH groups
- Polymer Meshes
 - Polyvinyl pyrrolidone (PVP), polyethyleneimine (PEI) and fatty Acids (glycerolmonooleate)


GENATIONAL LABORATORY







Sulfur Bond on the Surface of Au, Ag or Cu










Silane Bonds on Hydroxyl Rich Surfaces



NOTE:

- Silane bond stability is a function of how densely the –OH groups are spaced on the target surface
- Sparse –OH groups on non silica surfaces will lead to no oxygen bridges between silica surface modifers


Biomaterials 35(6) · December 2013 DOI: 10.1016/j.biomaterials.2013.11.047







Polymer capping of Quantum Dots and Carbon Dots



1. Displace low molecular weight Ligand

2. Cross link Dextran on Surface

NOTE:

Can also be used to electrostatically adsorb monomers on surface of nanoparticles followed by crosslinking.

Chem. Mater. 2010, 22, 6361-6369 6361






OAK RIDGE NATIONAL LABORATORY Managed by UT-Battelle for the Department of Energy



Polymer Meshes and Fatty Acid Capping



DOI: <u>10.1039/C6TB01659F</u> (Paper) <u>J. Mater.</u> <u>Chem. B</u>, 2016, **4**, 5418-5428







Online Resources for Surface Modifying Groups

ATIONAL LABORATORY

- Thiols/ Polymers
 - Sigma-Aldrich (Key Word: Functional thiols)
- Silanes
 - Gelest (Key word: Orthosilicate)
- Fatty acid
 - Avanti Polar Lipds







Outline of the talk

• Section I

- Common chemical techniques employed to modify surface of nanoparticles
 - Thiols, Silanes, polymeric monomers and hybrid schemes

• Section II

- Characterization of chemical functional groups on nanoparticles


- Section III
 - Common conjugation techniques
- Section IV
 - Published examples of how surfaces are modified to meet end user needs
- Section V
 - Interesting reads







¹H-NMR to Determine Ratio of Organic Molecules on the Surface of NPs – Qualitative Test



The mole ratio of MUA: MCH: Citrate = $1^{\circ}3^{\circ}30$





Anal.Chem. 79, 7708-7718 (2007)



Managed by UT-Battelle for the Department of Energy







Nanoscale, 2015, 7, 6545-6555







Outline of the talk

• Section I

- Common chemical techniques employed to modify surface of nanoparticles
 - Thiols, Silanes, polymeric monomers and hybrid schemes

• Section II

- Characterization of chemical functional groups on nanoparticles
 - NMR and FT-IR (Qualitative); Thermogravimetry (Quantitative)
- Section III

- Common conjugation techniques


- Section IV
 - Published examples of how surfaces are modified to meet end user needs
- Section V
 - An insight into where future functionalization might be headed







Activating Functional Groups for Further Chemical Modifications









Common Conjugation Chemistries

- Carbodiimide/Succinimide and NHS esters
 - Activate carboxylic acid (-COOH) to react with amine (NH₃)
- Isothiocyanate
 - Will react with amines and alcohol in that order of preference

ATIONAL LABORATORY

- Maleimide
 - Reacts with Sulfhydryl groups
- 'CLICK' Chemistry
 - Copper catalyzed
 - Copper free

Bioconjugation techniques http://www.sciencedirect.com/science/book/9 780123822390







Functional Targets on Biomolecules

- Proteins and Peptides
 - Amines (-NH₃), thiols (-SH), carboxylic acid (-COOH), Hydroxyl group on glycans (-OH)

TIONAL LABORATORY

- Carbohydrates and glycoconjugates
 - Hydroxyl groups (-OH) and aldehydes (-CHO)


- DNA/RNA and nucleotides
 - 5' phosphate group or <mark>3' –OH group</mark>







Carbodiimide Chemistry: Links –COOH to NH₃



Advantages

- Cheap
- Well characterized reaction
- Useful for crosslinking reactions

Disadvantages


- Highly susceptible to water hydrolysis
- The by product is a toxic urea compound








Carbodiimide/Succinimide: Links –COOH to NH₃



Isothiocyanate [N=C=S] Reacts with [NH₃]




Advantages

- Well characterized reaction
- Useful for fluorescently tagging protein
- Occurs in physiological pH

Disadvantages

- Highly susceptible to water hydrolysis
- Also reacts with alcohol




Chemical Formula: C₂₁H₁₁NO₅S Molecular Weight: 389.38

CO₂H H₂N

Chemical Formula: C₃H₇NO₂ Molecular Weight: 89.09

DIEA, FW 129, d=0.747




Chemical Formula: C₂₄H₁₈N₂O₇S Molecular Weight: 478.47







Reductive Amination of Aldehyde [-CHO]



Advantages

- Well characterized reaction
- Reacts with amines
- Occurs in physiological pH
- Suitable for oligonucleotide and carbohydrate conjugations

Disadvantages

Not suited for protein conjugations


https://www.google.com/patents/US6500921







Maleimide: Reacts with Sulfhydryl (-SH) group



Advantages

- Highly stable at physiological pH, up to 3 days
- Well characterized reaction
- Useful for protein linking experiment
- Amide formation occurs at Physiological pH

Disadvantages

- If there are disulfide bridges, no reaction will occur
- Can inactivate antibodies by disrupting sulfide links between the stem and arm region


http://www.genelink.com/newsite/products/mod_detail.asp?modid=226







'CLICK' Chemistry – Copper Catalyzed



Advantages

- Well characterized reaction
- Easy to Store
- Amenable to wide range of solvents

Disadvantages

- Needs copper as catalysts. Potential toxicity


http://medchem101.com/?page_id=142







'CLICK Chemistry'- Copper free Strain Promoted



Advantages

- Well characterized reaction
- Easy to Store
- Amenable to wide range of solvents

Disadvantages - Other than expense none


http://medchem101.com/?page_id=142







'CLICK Chemistry'- Copper free Thiol-ene Reaction



Disadvantages

- Thiols have a propensity to form –S-S (disulfide bridges) which reduces their reactivity

http://www.advancedsciencenews.com/novel-polymeric-ionic-liquids-through-clickchemistry/









Conjugation Linkers With Spacers

- Homobifunctional Linkers
 - Cross-linking materials to vary stiffness and strength
- Heterobifunctional
 - Introducing functional groups like streptavidin on surface for further modification





https://www.gbiosciences.com/Protein-Research/Cross-Linking-Modification/Protein-Cross-Linkers/Homobifunctional-Cross-Linkers

http://www.biosyn.com/faq/do-you-offerazide-or-an-alkyne-modified-dnasequence.aspx









Major Types of Bioconjugates

- Antibody-enzyme conjugates
- Antibody-drug conjugates
- Fluorescently labeled antibodies
- (Streo)avidin-enzyme conjugates
- Fluorescently-labeled (strept)avidin
- PEGylated drugs or proteins
- Antibody-(nano)particle conjugates for assay or detection
- Immobilized affinity ligands for assay or purification
- Hapten-Carrier Conjugates for vaccines or antibody production
- Fluorescently labeled nucleotides or oligos for next-gen sequencing, PCR or hybridization assays







How to Create an Optimal Bioconjugate

- Design the conjugate with the final application in mind
 - Do a small performance test
- Review literature for starting points on reagents, reactions and conditions
- Use solvents that are appropriate for the reagent and reaction conditions
- Reaction conditions that yield maximum active conjugates are important
- Optimize storage conditions to ensure long term stability
- Make several batches using final process to ensure reproducibility







Outline of the talk

• Section I

- Common chemical techniques employed to modify surface of nanoparticles
 - Thiols, Silanes, polymeric monomers and hybrid schemes
- Section II
 - Characterization of chemical functional groups on nanoparticles
 - NMR and FT-IR
- Section III
 - Common conjugation techniques
 - Carbodiimide, NHS ester, Maleimide, Isothiocyanate, thiolene, Copper free or copper catalyzed CLICK
- Section IV
 - Published examples of how surfaces are modified to meet end user needs
- Section V
 - Interesting reads







Surface Modifications to Match End User Applications

- NOTE: Always account for cross-reactivity when using multiple functional groups
- Stability of functional groups on the surface is always a concern
- Simultaneous incorporation of florescence and reactive functional groups on silica particles
- In situ Synthesis of Functional Groups on the surface of the Nanoparticles
- Biodistribution
- Biosensors
- Immuno Targeting







1. Fluorescent Silica Nanoparticles




Table 3 Hydrodynamic sizes and zeta potentials and plain and Alexa Fluor dye doped SiO₂ nanoparticles before and after surface functionalization

Size (nm) \pm polydispersity (%)			ζ (mV) \pm half width (mV)		
Non-modified	-COOH modified	-NH ₂ modified	Non-modified	-COOH modified	-NH ₂ modified
37.4 ± 7.2	38.2 ± 8.8	361 ± 27.1	-38.3 ± 3.6	-49.5 ± 4.2	16.5 ± 4.5
62.4 ± 11.2	38.9 ± 9.7	574 ± 23.6	-32.1 ± 3.3	-48.2 ± 3.7	20.1 ± 4.1
78.8 ± 14.2	39.6 ± 9.2	688 ± 24.2	-30.7 ± 3.4	-43.8 ± 4.6	11.8 ± 4.3
68.2 ± 13.8	38.5 ± 7.9	721 ± 26.6	-36.8 ± 3.2	-44.3 ± 3.3	$12.2 \pm 4.2 \\ 18.2 \pm 3.7$
	Non-modified 37.4 ± 7.2 62.4 ± 11.2 78.8 ± 14.2 68.2 ± 13.8	Non-modified-COOH modified 37.4 ± 7.2 38.2 ± 8.8 62.4 ± 11.2 38.9 ± 9.7 78.8 ± 14.2 39.6 ± 9.2 68.2 ± 13.8 38.5 ± 7.9	Non-modified-COOH modified $-NH_2$ modified 37.4 ± 7.2 38.2 ± 8.8 361 ± 27.1 62.4 ± 11.2 38.9 ± 9.7 574 ± 23.6 78.8 ± 14.2 39.6 ± 9.2 688 ± 24.2 68.2 ± 13.8 38.5 ± 7.9 721 ± 26.6	Non-modified-COOH modified-NH2 modifiedNon-modified 37.4 ± 7.2 38.2 ± 8.8 361 ± 27.1 -38.3 ± 3.6 62.4 ± 11.2 38.9 ± 9.7 574 ± 23.6 -32.1 ± 3.3 78.8 ± 14.2 39.6 ± 9.2 688 ± 24.2 -30.7 ± 3.4	Non-modified-COOH modified-NH2 modifiedNon-modified-COOH modified 37.4 ± 7.2 38.2 ± 8.8 361 ± 27.1 -38.3 ± 3.6 -49.5 ± 4.2 62.4 ± 11.2 38.9 ± 9.7 574 ± 23.6 -32.1 ± 3.3 -48.2 ± 3.7 78.8 ± 14.2 39.6 ± 9.2 688 ± 24.2 -30.7 ± 3.4 -43.8 ± 4.6 68.2 ± 13.8 38.5 ± 7.9 721 ± 26.6 -36.8 ± 3.2 -44.3 ± 3.3


 a Average particle sizes are 32 \pm 2.5 nm determined by SEM images. The DLS and ζ measurements were performed in 1 mM KCl solution at pH = 7.0 \pm 0.2.

OAK RIDGE NATIONAL LABORATORY

Nanoscale, 2013, 5, 10369-10375




С





Fluorescent Silica Nanoparticles











2. Problem: Comparing the biodistribution of radiolabeled Silica and radiolabeled Iron Oxide NPs



- SiO_2 volume labeled with ¹⁴C
- Surface functionalized with -COO-



We needed surface similar ¹⁴C labeled Fe_3O_4 NPs to do a comparative study

IVERSITY OF

http://www.nd.edu/~amebio


How do we radiolabel the Fe₃O₄ NPs without altering the surface functional groups ?

Nanoscale, 2015, 7, 6545-6555





Solution: Synthesize –COO- Functional Groups In Situ with Radiolabeled Precursors




Nanoscale, 2015, 7, 6545-6555








3. In Vivo Bio-Distribution of ¹⁴C Labeled NPs



Dose: 44mg Fe-Si-(¹⁴COO-)₃/hour **Time:** 4 hours




Nanoscale, 2015, 7, 6545-6555





UNIVERSITY OF NOTRE DAME http://www.nd.edu/~amebio

4. Design of Nanoparticle BioSensor




The mole ratio of MUA: MCH: Citrate = 1: 3: 30

Analytical Chemistry doi:10.1021/ac0709706




А








Imaging and Sensing Single Receptors on Single Living Cells



Anal.Chem. 79, 7708-7718 (2007)



15.0

15.0

OF

H

http://www.nd.edu/~amebio


F





Managed by UT-Battelle for the Department of Energy

5. Immunotargeted Binding to SKOV3-IP Cells



SKOV3-IP CD133 (+) cells






OAK RIDGE NATIONAL LABORATORY
Managed by UT-Battelle for the Department of Energy



Binding Specificity of Immunotargeted Binding to SKOV3-IP Cells







Managed by UT-Battelle for the Department of Energy



Outline of the talk

• Section I

- Common chemical techniques employed to modify surface of nanoparticles
 - Thiols, Silanes, polymeric monomers and hybrid schemes
- Section II
 - Characterization of chemical functional groups on nanoparticles
 - NMR and FT-IR
- Section III
 - Common conjugation techniques
 - Carbodiimide, NHS ester, Maleimide, Isothiocyanate, thiolene, Copper free or copper catalyzed CLICK
- Section IV
 - Published examples of how surfaces are modified to meet end user needs
- Section V
 - Interesting reads







CRISPR-Cas9 for Gene Editing and Diagnostics

nature biomedical engineering

ARTICLES DOI: 10.1038/s41551-017-0137-2

Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed **DNA** repair

Kunwoo Lee¹, Michael Conboy², Hyo Min Park¹, Fuguo Jiang³, Hyun Jin Kim^{2,4,5}, Mark A. Dewitt^{3,6}, Vanessa A. Macklev^{1,2}, Kevin Chang³, Anirudh Rao³, Colin Skinner², Tamanna Shobha², Melod Mehdipour², Hui Liu¹, Wen-chin Huang², Freeman Lan², Nicolas L. Bray^{3,6}, Song Li², Jacob E. Corn 34, Kazunori Kataoka 4.5.7, Jennifer A. Doudna 3,6,8,9,10, Irina Conboy2* and Niren Murthy2*

Clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 (Cas9)-based therapeutics, especially those that can correct gene mutations via homology-directed repair, have the potential to revolutionize the treat-ment of genetic diseases. However, it is challenging to develop homology-directed repair-based therapeutics because they require the simultaneous in vivo delivery of Cas9 protein, guide RNA and donor DNA. Here, we demonstrate that a delivery vehicle composed of gold nanoparticles conjugated to DNA and complexed with cationic endosomal disruptive polymers can deliver Cas9 ribonucleoprotein and donor DNA into a wide variety of cell types and efficiently correct the DNA mutation that causes Duchenne muscular dystrophy in mice via local injection, with minimal off-target DNA damage.

ene-editing therapeutics based on the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 (Cas9) system have tremendous potential for treating genetic diseases1-4. Primarily, two types of geneediting therapies are being considered for the CRISPR-Cas9 system: therapies based on non-homologous end joining, which permanently silence disease-causing genes by inducing indel mutations, and therapies based on homology-directed repair (HDR), which correct disease-causing gene mutations to their wild-type sequence. HDR-based therapies have the potential to cure the vast majority of genetic diseases because of this mechanism of action. There is therefore great interest in developing HDR-based therapeutics. However, gene editing via HDR in vivo is challenging because HDR requires the delivery of Cas9, guide RNA (gRNA) and donor DNA.

Gene therapy with adeno-associated viruses (AAVs) is currently the most advanced methodology for delivering Cas9 in vivo54. However, developing Cas9 therapeutics based on AAV delivery is challenging because a large fraction of the human population has pre-existing immunity towards AAV, making them ineligible for AAV-based therapies. In addition, AAV-based Cas9 delivery has the potential to cause significant off-target genomic damage due to the sustained expression of Cas9 (refs 78). AAV also has a small packing size and multiple viruses are needed to deliver Cas9 ribonucleoprotein (RNP) and donor DNA in vivo, which decreases the HDR efficiency of AAV-based Cas9-delivery methods. Finally, although AAV-based Cas9 delivery has generated several exciting pre-clinical demonstrations in vivo9-11, the viral titers needed to generate therapeutic levels of editing have been orders of magnitude higher than the clinically accepted levels.

There is therefore great interest in developing non-viral Cas9based therapeutics that can induce HDR12. However, developing delivery vehicles that can induce HDR in vivo has been challeng ing because of the multiple components involved. The only nonviral demonstration of HDR in vivo has been via the hydrodynamic delivery of plasmid DNA that expresses Cas9, gRNA and donor DNA13. The translational potential of hydrodynamic-based delivery of plasmids is unclear because of the dramatic changes in blood pressure that it causes.

Direct delivery of the Cas9 RNP is also being considered as a therapeutic strategy for generating HDR and has tremendous mise for clinical translation¹⁴ because of the established protocols for producing proteins on a large scale and for clinical use, and because of the well-characterized clinical track record of protein therapeutics. Delivery strategies have been developed for delivering the Cas9 RNP in vitro and in vivo¹⁵⁻¹⁸. Lipofectamine and polyethylenimine have been the most successful Cas9 RNP delivery vehicles and have been able to deliver Cas9 RNP into the ear and in tumours to knock-out genes via non-homologous end joining. However, the application of lipid products or polyethylenimine to induce HDR in vivo has not been successfully demonstrated and will be potentially problematic due to the challenges associated with delivering multiple macromolecules in vivo. Therefore, the development of

GenEdit, Berkeley, CA 94720-0001, USA. 2Department of Bioengineering, University of California, Berkeley, Berkeley, CA 94720, USA. 2Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA. 4Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan. "Department of Materials Engineering, Graduate School of Engineering The University of Tokyo, Tokyo 113-0033, Japan, 4Innovative Genomics Initiative, University of California, Berkeley, CA 94720, USA. Innovation Center of NanoMedicine, Institute of Industry Promotion-KAWASAKI, Kawasaki 210-0821, Japan. "Howard Hughes Medical Institute, itv of California Rerkelev Rerkelev CA 94720 USA *Denartment of Chemistry University of California Rerkelev CA 97420-1460, USA

DOI: 10.1038/s41551-017-0137-2

nature biotechnology

https://doi.org/10.1038/s41587-020-0513-4

Check for update

LETTERS

CRISPR-Cas12-based detection of SARS-CoV-2

James P. Broughton¹⁷, Xianding Deng^{2,3,7}, Guixia Yu^{2,3}, Clare L. Fasching¹, Venice Servellita^{2,3}, Jasmeet Singh¹, Xin Miao¹, Jessica A. Streithorst², Andrea Granados^{2,3}, Alicia Sotomayor-Gonzalez^{2,3}, Kelsey Zorn⁴, Allan Gopez², Elaine Hsu², Wei Gu², Steve Miller², Chao-Yang Pan⁵, Hugo Guevara⁵, Debra A. Wadford⁵, Janice S. Chen^{©1}[™] and Charles Y. Chiu^{®2,3,6}[™]

An outbreak of betacoronavirus severe acute respiratory syndrome (SARS)-CoV-2 began in Wuhan, China in December 2019. COVID-19, the disease associated with SARS-CoV-2 infection, rapidly spread to produce a global pandemic. We report development of a rapid (<40 min), easy-to-implement and accurate CRISPR-Cas12-based lateral flow assay for detection of SARS-CoV-2 from respiratory swab RNA extracts. We validated our method using contrived reference samples and clinical samples from patients in the United States, including 36 patients with COVID-19 infection and 42 patients with other viral respiratory infections. Our CRISPR-based DETECTR assay provides a visual and faster alternative to the US Centers for Disease Control and Prevention SARS-CoV-2 real-time RT-PCR assay, with 95% positive predictive agreement and 100% negative predictive agreement.

Over the past 40 years, there have been recurrent large-scale epidemics from emerging viruses such as HIV, SARS and Middle East respiratory syndrome coronaviruses, 2009 pandemic influenza H1N1 virus, Ebola virus, Zika virus and most recently SARS-CoV-2 (refs. 1,2). All of these epidemics most likely resulted from an initial zoonotic animal-to-human transmission event, with either clinically apparent or occult spread into vulnerable human populations. Each time, a lack of rapid, accessible and accurate molecular diagnostic testing has hindered the public health response to the emerging viral threat.

COVID-19), was reported in Wuhan, China12. This outbreak has spread rapidly, with over 1.2 million reported cases and 64,500 deaths worldwide as of 4 April 2020 (ref. 3). Person-to-person transmission from infected individuals with no or mild symptoms has been reported⁴⁵. Assays using quantitative RT-PCR (qRT-PCR) approaches for detection of the virus in 4-6h have been developed by several laboratories, including an emergency use authorization (EUA)-approved assay developed by the US Centers for Disease Control and Prevention (CDC)6, However, the typical turnaround time for screening and diagnosing patients with suspected SARS-CoV-2 has been >24h, given the need to ship samples overnight to reference laboratories. Although serology tests are rapid and require minimal equipment, their utility may be limited for diagnosis of acute SARS-CoV-2 infection, because it can take several days to weeks following symptom onset for a patient to mount a detectable antibody response7. To accelerate clinical diagnostic testing for

COVID-19 in the United States, on 28 February 2020, the US Food and Drug Administration (FDA) permitted individual clinically licensed laboratories to report the results of in-house-developed SARS-CoV-2 diagnostic assays while awaiting results of an EUA submission for approval

Here we report the development and initial validation of a CRISPR-Cas12-based assay5-13 for detection of SARS-CoV-2 from extracted patient sample RNA, called SARS-CoV-2 DNA Endonuclease-Targeted CRISPR Trans Reporter (DETECTR). This assay performs simultaneous reverse transcription and isothermal amplification using loop-mediated amplification (RT-LAMP)³ for RNA extracted from nasopharyngeal or oropharyngeal swabs in universal transport medium (UTM), followed by Cas12 detection of predefined coronavirus sequences, after which cleavage of a reporter molecule confirms detection of the virus. We first designed primers targeting the E (envelope) and N (nucleoprotein) genes of SARS-CoV-2 (Fig. 1a). The primers amplify regions that overlap the World Health Organization (WHO) assay (E gene region) and US CDC assay (N2 region in the N gene)415, but are modified to meet design requirements for LAMP. We did not target the N1 and N3 regions used by the US CDC assay, as these regions lacked suitable protospacer adjacent motif sites for the Cas12 guide RNAs (gRNAs). Next, we designed Cas12 gRNAs to detect three SARS-like coronaviruses (SARS-CoV-2 (accession NC 045512), bat SARS-like coronavirus (bat-SL-CoVZC45, accession MG772933) and SARS-In early January 2020, a cluster of cases of pneumonia from a CoV (accession NC 004718)) in the E gene and specifically detect new coronavirus, SARS-CoV-2 (with the disease referred to as only SARS-CoV-2 in the N gene (Supplementary Fig. 1). This design is similar to those used by the WHO and US CDC assays, which use multiple amplicons with probes that are either specific to SARS-CoV-2 or are capable of identifying related SARS-like coronaviruses

Using synthetic, in vitro-transcribed (IVT) SARS-CoV-2 RNA gene targets in nuclease-free water, we demonstrated that CRISPR-Cas12-based detection can distinguish SARS-CoV-2 with no cross-reactivity for related coronavirus strains using N gene gRNA and with expected cross-reactivity for E gene gRNA (Fig. 1b and Supplementary Fig. 2). We then optimized conditions for the SARS-CoV-2 DETECTR assay on the E gene, N gene and human RNase P gene as a control, which consists of an RT-LAMP reaction at 62°C for 20-30 min and Cas12 detection reaction at 37°C for 10min. The DETECTR assay can be run in approximately 30-40 min and visualized on a lateral flow strip (Fig. 1c,d). The SARS-CoV-2 DETECTR assay is considered positive if there is detection of both the E and N genes or presumptive positive if there



NATURE BIOTECHNOLOGY I www.nature.com/naturebioted








Managed by UT-Battelle for the Department of Energy

Advances in the Development of Site-Specific Antibody-Drug Conjugation



Rapid BioAssays – Environmental Monitoring of E.Coli



Analyst, 2016, 141, 2920







Remote Stem Cell Guidance and Differentiation




Fig. 1 Schematic illustrating the different steps involved in the magnetic stretcher. a Nanoparticles incorporation in ESCs, b EBs formation from magnetized ESCs driven by a magnetic microtip, and c EBs magnetic stimulation in situ, in the 3D geometry, and without the need for a supporting matrix

DOI: 10.1038/s41467-017-00543-2








Incorporating Molecular Machines on Surfaces

Molecular machines open cell membranes

Víctor García–López^{1,2}, Fang Chen³, Lizanne G. Nilewski^{1,2}, Guillaume Duret⁴, Amir Aliyan¹, Anatoly B. Kolomeisky¹, Jacob T. Robinson⁴, Gufeng Wang³, Robert Pal⁵ & James M. Tour^{1,2,6}



doi:10.1038/nature23657







Outline of the talk

- Section I
 - Common chemical techniques employed to modify surface of nanoparticles
 - Thiols, Silanes, polymeric monomers and hybrid schemes
- Section II
 - Characterization of chemical functional groups on nanoparticles
 - NMR and FT-IR
- Section III
 - Common conjugation techniques
 - Carbodiimide, NHS ester, Maleimide, Isothiocyanate, thiolene, Copper free or copper catalyzed CLICK
- Section IV
 - Published examples of how surfaces are modified to meet end user needs
- Section V
 - Interesting reads





